Pirfenidone in the treatment of idiopathic pulmonary fibrosis: An evidence-based review of its place in therapy

Core Evidence

Volumn 11, Issue , 2016, Pages 11-22

  Margaritopoulos, George A ^a   Vasarmidi, Eirini ^b   Antoniou, Katerina M ^b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Antifibrotic; Nausea; Photosensitivity; Pirfenidone

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; MUCIN 5B; NINTEDANIB; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUSE OF DEATH; DECREASED APPETITE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; JAPANESE (PEOPLE); LOSS OF APPETITE; LOSS OF FUNCTION MUTATION; MUC5B GENE; MULTICENTER STUDY (TOPIC); MYOFIBROBLAST; NAUSEA; NONHUMAN; OBSERVATIONAL STUDY; OPEN STUDY; OVERALL SURVIVAL; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

EID: 84991648540     PISSN: 15551741     EISSN: 1555175X     Source Type: Journal    
DOI: 10.2147/CE.S76549     Document Type: Review

References (73)

1. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet. 2011;377:1760-1769.
2. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-2092.
3. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-2082.
4. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
5. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3-e19.
6. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2:566-572.
7. Margaritopoulos GA, Giannarakis I, Siafakas NM, et al. An update on idiopathic pulmonary fibrosis. Panminerva Med. 2013;55:109-120.
8. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134:136-151.
9. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J. 2007;30:835-839.
10. Armanios M. Syndromes of telomere shortening. Ann Rev Genomics Hum Genet. 2009;10:45-61.
11. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;309:2232-2239.
12. Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: A genome-wide association study. Lancet. 2013;1:309-317.
13. Margaritopoulos GA, Harari S, Caminati A, Antoniou KM. Smoking-related idiopathic interstitial pneumonia: A review. Respirology. 2016;21:57-64.
14. Lasithiotaki I, Antoniou KM, Vlahava VM, et al. Detection of herpes simplex virus type-1 in patients with fibrotic lung diseases. Plos One. 2011;6:e27800.
15. Molyneaux PL, Cox MJ, Willis-Owen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190:906-913.
16. Tcherakian C, Cottin V, Brillet PY, et al. Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. Thorax. 2011;66:226-231.
17. Lee JS, Collard HR, Anstrom KJ, et al. Anti-Acid treatment and disease progression in idiopathic pulmonary fibrosis: An analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1(5):369-376.
18. Andersson-Sjöland A, de Alba CG, Nihlberg K, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol. 2008;40:2129-2140.
19. Antoniou KM, Papadaki HA, Soufla G, et al. Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in Idiopathic Pulmonary Fibrosis (IPF). Respir Med. 2010;104:1535-1542.
20. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res. 2011;157:191-199.
21. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: A disease with similarities and links to cancer biology. Eur Respir J. 2010;35:496-504.
22. American Thoracic Society; European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. Am J Respir Crit Care Med. 2000;161:646-664.
23. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229-2242.
24. Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-Acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968-1977.
25. Idiopathic Pulmonary Fibrosis Clinical Research Network; Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2093-3101.
26. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125-133.
27. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): A multicentre, randomised, placebo-controlled trial. Lancet. 2009;374:222-228.
28. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: An exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008;178:948-955.
29. Noth I, Anstrom KJ, Calvert SB, et al. The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186:88-95.
30. King TE, Behr J, Brown KK, et al. BUILD-1: A randomized placebocontrolled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:75-81.
31. King TE, Brown KK, Raghu G, et al. BUILD-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184:92-99.
32. Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomized controlled MUSIC trial. Eur Respir J. 2013;42:1622-1632.
33. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: A parallel, randomized trial. Ann Intern Med. 2013;158:641-649.
34. Zisman DA, Schwarz M, Anstrom KJ, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363:620-628.
35. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010;181:604-610.
36. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079-1087.
37. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821-829.
38. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-Term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999;341:1264-1269.
39. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005;128:1475-1482.
40. Tzouvelekis A, Margaritopoulos G, Loukides S, Bouros D. Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin? Am J Respir Crit Care Med. 2013;187:213-214.
41. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774-4782.
42. Nakayama S, Mukae H, Sakamoto N, et al. Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci. 2008;82:210-217.
43. Di Sario A, Bendia E, Svegliati Baroni G, et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol. 2002;37:584-591.
44. Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13-19.
45. Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-Alpha at the translational level. Eur J Pharmacol. 2002;446:177-185.
46. Oku H, Nakazato H, Horikawa T, Tsuruta Y, Suzuki R. Pirfenidone suppresses tumor necrosis factor-Alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol. 2002;446:167-176.
47. Cain WC, Stuart RW, Lefkowitz DL, Starnes JD, Margolin S, Lefkowitz SS. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol. 1998;20:685-695.
48. Hale ML, Margolin SB, Krakauer T, Roy CJ, Stiles BG. Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infect Immun. 2002;70:2989-2994.
49. Giri SN, Leonard S, Shi X, Margolin SB, Vallyathan V. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol. 1999;18:169-177.
50. Misra HP, Rabideau C. Pirfenidone inhibits NADPH dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem. 2000;204:119-126.
51. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med. 1995;125:779-785.
52. Iyer SN, Margolin SB, Hyde DM, Giri SN. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res. 1998;24:119-132.
53. Kakugawa T, Mukae H, Hayashi T, et al. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J. 2004;24:57-65.
54. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label phase II study. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1061-1069.
55. Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T. Open-label compassionate use one year-Treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med. 2002;41:1118-1123.
56. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040-1047.
57. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2010;9:CD003134.
58. European Medicines Agency. EPAR - product information. London: European Medicines Agency; 2011. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document-detail.jsp?webContentId=WC500103049&mid=WC0b01ac058009a3dc Accessed May 17, 2016.
59. Margaritopoulos G. Challenges in IPF diagnosis, current management and future perspectives: Patient case 2. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32 (Suppl 1):38-39.
60. Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: Expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014;31:375-391.
61. Costabel U, Albera C, Cohen A, et al. The long-Term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): interim data from the RECAP extension study. Eur Respir J. 2011;38 (Suppl 55):174s.
62. Costabel U, Albera C, Bradford WZ, et al. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31:198-205.
63. Koschel D, Cottin V, Skold M, et al. Pirfenidone post-Authorisation safety registry (PASSPORT) - interim analysis of IPF treatment. Eur Respir J. 2014;44 (Suppl 58):1904.
64. Harari S, Caminati A, Albera C, et al. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study. Respir Med. 2015;109:904-913.
65. Ley B, Ryerson CJ, Wittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156:684-691.
66. Wijsenbeek MS, Grutters JC, Wuyts WA. Early experience of pirfenidone in daily clinical practice in Belgium and the Netherlands: A retrospective cohort analysis. Adv Ther. 2015;32:691-704.
67. Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-Term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014;19:740-748.
68. Chaudhuri N, Duck A, Frank R, et al. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108:224-226.
69. Antoniou KM, Symvoulakis EK, Margaritopoulos GA, et al. Early diagnosis of IPF: Time for a primary-care case-finding initiative? Lancet Respir Med. 2014;2:e1.
70. Fell CD, Martinez FJ, Liu LX, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010;181:832-837.
71. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733-748.
72. Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1382-1392.
73. Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: The future of management for idiopathic pulmonary fibrosis? Lancet Respir Med. 2014;2:933-942.